INVITED REVIEW
Advanced Computed Tomography and Magnetic Resonance Imaging in Ischemic and Nonischemic Cardiomyopathies
Farah Tamizuddin,
Jadranka Stojanovska,
Danielle Toussie,
Anna Shmukler,
Leon Axel,
Ranjini Srinivasan,
Kana Fujikura,
Jordi Broncano,
Luba Frank,
Geraldine Villasana-Gomez,
Corresponding Author
Farah Tamizuddin
Department of Radiology, New York Langone Health, New York, New York, USA
Correspondence: Farah Tamizuddin ([email protected])
Search for more papers by this authorJadranka Stojanovska
Department of Radiology, New York Langone Health, New York, New York, USA
Search for more papers by this authorDanielle Toussie
Department of Radiology, New York Langone Health, New York, New York, USA
Search for more papers by this authorAnna Shmukler
Department of Radiology, New York Langone Health, New York, New York, USA
Search for more papers by this authorLeon Axel
Department of Radiology, New York Langone Health, New York, New York, USA
Search for more papers by this authorRanjini Srinivasan
Department of Cardiology, New York Langone Health, New York, New York, USA
Search for more papers by this authorKana Fujikura
Department of Cardiology, New York Langone Health, New York, New York, USA
Search for more papers by this authorJordi Broncano
Cardiothoracic Imaging Unit, Hospital San Juan de Dios, HT Medica, Córdoba, Spain
Search for more papers by this authorLuba Frank
Baylor College of Medicine, Baylor St. Luke's Medical Center and Texas Heart Institute Department of Radiology Cardiovascular Imaging Section Houston, Texas, USA
Search for more papers by this authorGeraldine Villasana-Gomez
Department of Radiology, New York Langone Health, New York, New York, USA
Search for more papers by this authorFarah Tamizuddin,
Jadranka Stojanovska,
Danielle Toussie,
Anna Shmukler,
Leon Axel,
Ranjini Srinivasan,
Kana Fujikura,
Jordi Broncano,
Luba Frank,
Geraldine Villasana-Gomez,
Corresponding Author
Farah Tamizuddin
Department of Radiology, New York Langone Health, New York, New York, USA
Correspondence: Farah Tamizuddin ([email protected])
Search for more papers by this authorJadranka Stojanovska
Department of Radiology, New York Langone Health, New York, New York, USA
Search for more papers by this authorDanielle Toussie
Department of Radiology, New York Langone Health, New York, New York, USA
Search for more papers by this authorAnna Shmukler
Department of Radiology, New York Langone Health, New York, New York, USA
Search for more papers by this authorLeon Axel
Department of Radiology, New York Langone Health, New York, New York, USA
Search for more papers by this authorRanjini Srinivasan
Department of Cardiology, New York Langone Health, New York, New York, USA
Search for more papers by this authorKana Fujikura
Department of Cardiology, New York Langone Health, New York, New York, USA
Search for more papers by this authorJordi Broncano
Cardiothoracic Imaging Unit, Hospital San Juan de Dios, HT Medica, Córdoba, Spain
Search for more papers by this authorLuba Frank
Baylor College of Medicine, Baylor St. Luke's Medical Center and Texas Heart Institute Department of Radiology Cardiovascular Imaging Section Houston, Texas, USA
Search for more papers by this authorGeraldine Villasana-Gomez
Department of Radiology, New York Langone Health, New York, New York, USA
Search for more papers by this authorFunding: The authors received no specific funding for this work.
ABSTRACT
Cardiomyopathies represent a diverse group of heart diseases that can be broadly classified into ischemic and nonischemic etiologies, each requiring distinct diagnostic approaches. Noninvasive imaging modalities, such as computed tomography (CT) and magnetic resonance imaging (MRI), play a pivotal role in the diagnosis, risk stratification, and prognosis of these conditions. This paper reviews the characteristic CT and MRI findings associated with ischemic cardiomyopathy (ICM) and nonischemic cardiomyopathy (NICM), focusing on their ability to provide detailed anatomical, functional, and tissue characterization. In ICM, CT and MRI reveal myocardial scarring, infarct size, and coronary artery disease, while MRI further distinguishes tissue viability through late gadolinium enhancement (LGE). Conversely, nonischemic cardiomyopathies demonstrate a wide array of findings, with MRI's LGE pattern analysis being particularly critical for identifying specific subtypes, such as restrictive, hypertrophic, or dilated cardiomyopathies. By comparing the strengths and limitations of these modalities, this paper highlights their complementary roles in improving diagnostic accuracy, risk stratification, prognosis, and therapeutic decision making in both ischemic and nonischemic cardiomyopathies.
Conflicts of Interest
The authors declare no conflicts of interest.
References
- 1K. C. Allman, L. J. Shaw, R. Hachamovitch, and J. E. Udelson, “Myocardial Viability Testing and Impact of Revascularization on Prognosis in Patients With Coronary Artery Disease and Left Ventricular Dysfunction: A Meta-Analysis,” Journal of the American College of Cardiology 39, no. 7 (2002): 1151–1158.
- 2G. Muscogiuri, A. I. Guaricci, N. Soldato, et al., “Multimodality Imaging of Sudden Cardiac Death and Acute Complications in Acute Coronary Syndrome,” Journal of Clinical Medicine 11, no. 19 (2022): 5663.
- 3W. Woodward, C. L. Johnson, S. Krasner, et al., “Long-Term Outcomes After Stress Echocardiography in Real World Practice: Five-Year Follow-Up of the UK Evarest Study,” European Heart Journal – Cardiovascular Imaging 26, no. 2 (2025): 187–196, https://doi.org/10.1093/ehjci/jeae291.
10.1093/ehjci/jeae291 Google Scholar
- 4S. Wang, P. Kim, H. Wang, et al., “Myocardial Blood Flow Quantification Using Stress Cardiac Magnetic Resonance Improves Detection of Coronary Artery Disease,” JACC Cardiovascular Imaging 17, no. 12 (2024): 1428–1441.
- 5A. Rozanski, R. J. H. Miller, D. Han, et al., “Comparative Predictors of Mortality Among Patients Referred for Stress Single-Photon Emission Computed Tomography Versus Positron Emission Tomography Myocardial Perfusion Imaging,” Journal of Nuclear Cardiology 32, no. 101811 (2024): 101811.
- 6S. Bhatti, A. Hakeem, M. A. Yousuf, H. R. Al-Khalidi, W. Mazur, and Y. Shizukuda, “Diagnostic Performance of Computed Tomography Angiography for Differentiating Ischemic Vs Nonischemic Cardiomyopathy,” Journal of Nuclear Cardiology 18, no. 3 (2011): 407–420.
- 7Z. S. Chunawala, A. Qamar, S. Arora, et al., “Prognostic Significance of Obstructive Coronary Artery Disease in Patients Admitted With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance,” European Journal of Heart Failure 24, no. 11 (2022): 2140–2149.
- 8J. I. Hoffman and G. D. Buckberg, “Pathophysiology of Subendocardial Ischaemia,” British Medical Journal 1, no. 5949 (1975): 76–79.
- 9A. F. L. Schinkel, D. Poldermans, V. Rizzello, et al., “Why Do Patients With Ischemic Cardiomyopathy and a Substantial Amount of Viable Myocardium Not Always Recover in Function After Revascularization?” Journal of Thoracic and Cardiovascular Surgery 127, no. 2 (2004): 385–390.
- 10R. Y. Kwong, Y. Ge, K. Steel, et al., “Cardiac Magnetic Resonance Stress Perfusion Imaging for Evaluation of Patients With Chest Pain,” Journal of the American College of Cardiology 74, no. 14 (2019): 1741–1755.
- 11J. Schwitter, C. M. Wacker, N. Wilke, et al., “MR-IMPACT II: Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary Artery Disease Trial: Perfusion-Cardiac Magnetic Resonance Vs. Single-Photon Emission Computed Tomography for the Detection of Coronary Artery Disease: A Comparative Multicentre, Multivendor Trial,” European Heart Journal 34, no. 10 (2013): 775–781.
- 12J. P. Greenwood, A. Kidambi, A. Zaman, et al., “Cardiovascular Magnetic Resonance Stress Perfusion Compared to Single-Photon Emission Computed Tomography (SPECT) in Patients With Left Main Stem Disease: A CE-MARC Substudy,” Journal of Cardiovascular Magnetic Resonance 14, no. S1 (2012): O93.
10.1186/1532-429X-14-S1-O93 Google Scholar
- 13E. Nagel, J. P. Greenwood, G. P. McCann, et al., “Magnetic Resonance Perfusion or Fractional Flow Reserve in Coronary Disease,” New England Journal of Medicine 380, no. 25 (2019): 2418–2428.
- 14A. Arbab-Zadeh and V. Fuster, “The Risk Continuum of Atherosclerosis and Its Implications for Defining CHD by Coronary Angiography,” Journal of the American College of Cardiology 68, no. 22 (2016): 2467–2478.
- 15P. J. Habib, J. Green, R. C. Butterfield, et al., “Association of Cardiac Events With Coronary Artery Disease Detected by 64-Slice or Greater Coronary CT Angiography: A Systematic Review and Meta-Analysis,” International Journal of Cardiology 169, no. 2 (2013): 112–120.
- 16L. Jespersen, A. Hvelplund, S. Z. Abildstrøm, et al., “Stable Angina Pectoris With no Obstructive Coronary Artery Disease Is Associated With Increased Risks of Major Adverse Cardiovascular Events,” European Heart Journal 33, no. 6 (2012): 734–744.
- 17A. Aslam, J. Stojanovska, U. S. Khokhar, et al., “Spontaneous Coronary Artery Dissection: An Underdiagnosed Clinical Entity-A Primer for Cardiac Imagers,” Radiographics 41, no. 7 (2021): 1897–1915.
- 18K. D. Knott, A. Seraphim, J. B. Augusto, et al., “The Prognostic Significance of Quantitative Myocardial Perfusion: An Artificial Intelligence-Based Approach Using Perfusion Mapping,” Circulation 141, no. 16 (2020): 1282–1291.
- 19B. Ibanez, S. James, S. Agewall, et al., “2017 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation: The Task Force for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation of the European Society of Cardiology (ESC),” European Heart Journal 39, no. 2 (2018): 119–177.
- 20F. Arslan, P. Damman, B. Zwart, et al., “2020 ESC Guidelines on Acute Coronary Syndrome Without ST-Segment Elevation: Recommendations and Critical Appraisal From the Dutch ACS and Interventional Cardiology Working Groups,” Netherlands Heart Journal 29, no. 11 (2021): 557–565.
- 21S. Pasupathy, T. Air, R. P. Dreyer, R. Tavella, and J. F. Beltrame, “Systematic Review of Patients Presenting With Suspected Myocardial Infarction and Nonobstructive Coronary Arteries,” Circulation 131, no. 10 (2015): 861–870.
- 22A. D. Wechalekar, J. D. Gillmore, and P. N. Hawkins, “Systemic Amyloidosis,” Lancet 387, no. 10038 (2016): 2641–2654.
- 23S. Oda, M. Kidoh, Y. Nagayama, et al., “Trends in Diagnostic Imaging of Cardiac Amyloidosis: Emerging Knowledge and Concepts,” Radiographics 40, no. 4 (2020): 961–981.
- 24J. J. Maleszewski, “Cardiac Amyloidosis: Pathology, Nomenclature, and Typing,” Cardiovascular Pathology 24, no. 6 (2015): 343–350.
- 25J. P. Donnelly and M. Hanna, “Cardiac Amyloidosis: An Update on Diagnosis and Treatment,” Cleveland Clinic Journal of Medicine 84, no. 12 suppl. 3 (2017): 12–26.
- 26P. Garcia-Pavia, C. Rapezzi, Y. Adler, et al., “Diagnosis and Treatment of Cardiac Amyloidosis. A Position Statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases,” European Journal of Heart Failure 23, no. 4 (2021): 512–526.
- 27A. M. Maceira, S. K. Prasad, P. N. Hawkins, M. Roughton, and D. J. Pennell, “Cardiovascular Magnetic Resonance and Prognosis in Cardiac Amyloidosis,” Journal of Cardiovascular Magnetic Resonance 10, no. 1 (2008): 54.
- 28A. M. Maceira, J. Joshi, S. K. Prasad, et al., “Cardiovascular Magnetic Resonance in Cardiac Amyloidosis,” Circulation 111, no. 2 (2005): 186–193.
- 29R. Fattori, G. Rocchi, F. Celletti, P. Bertaccini, C. Rapezzi, and G. Gavelli, “Contribution of Magnetic Resonance Imaging in the Differential Diagnosis of Cardiac Amyloidosis and Symmetric Hypertrophic Cardiomyopathy,” American Heart Journal 136, no. 5 (1998): 824–830.
- 30I. S. Syed, J. F. Glockner, D. Feng, et al., “Role of Cardiac Magnetic Resonance Imaging in the Detection of Cardiac Amyloidosis,” JACC Cardiovascular Imaging 3, no. 2 (2010): 155–164.
- 31S. Bhogal, V. Ladia, P. Sitwala, et al., “Cardiac Amyloidosis: An Updated Review With Emphasis on Diagnosis and Future Directions,” Current Problems in Cardiology 43, no. 1 (2018): 10–34.
- 32B. A. Austin, W. H. W. Tang, E. R. Rodriguez, et al., “Delayed Hyper-Enhancement Magnetic Resonance Imaging Provides Incremental Diagnostic and Prognostic Utility in Suspected Cardiac Amyloidosis,” JACC Cardiovascular Imaging 2, no. 12 (2009): 1369–1377.
- 33H. Mahrholdt, A. Wagner, R. M. Judd, U. Sechtem, and R. J. Kim, “Delayed Enhancement Cardiovascular Magnetic Resonance Assessment of Non-Ischaemic Cardiomyopathies,” European Heart Journal 26, no. 15 (2005): 1461–1474.
- 34T. Pandey, K. Jambhekar, R. Shaikh, S. Lensing, and S. Viswamitra, “Utility of the Inversion Scout Sequence (TI Scout) in Diagnosing Myocardial Amyloid Infiltration,” The International Journal of Cardiovascular Imaging 29, no. 1 (2013): 103–112.
- 35M. Fontana, A. Ćorović, P. Scully, and J. C. Moon, “Myocardial Amyloidosis: The Exemplar Interstitial Disease,” JACC Cardiovascular Imaging 12, no. 11 pt. 2 (2019): 2345–2356.
- 36A. Ioannou, R. K. Patel, Y. Razvi, et al., “Multi-Imaging Characterization of Cardiac Phenotype in Different Types of Amyloidosis,” JACC Cardiovascular Imaging 16, no. 4 (2023): 464–477.
- 37J. A. Pan, M. J. Kerwin, and M. Salerno, “Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis: A Meta-Analysis,” JACC Cardiovascular Imaging 13, no. 6 (2020): 1299–1310.
- 38A. Ioannou, R. K. Patel, A. Martinez-Naharro, et al., “Tracking Treatment Response in Cardiac Light-Chain Amyloidosis With Native T1 Mapping,” JAMA Cardiology 8, no. 9 (2023): 848–852.
- 39A. Porcari, A. Masi, A. Martinez-Naharro, et al., “Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis,” JAMA Cardiology 9, no. 11 (2024): 982–989, https://doi.org/10.1001/jamacardio.2024.2555.
- 40K. Wan, J. Sun, D. Yang, et al., “Left Ventricular Myocardial Deformation on Cine MR Images: Relationship to Severity of Disease and Prognosis in Light-Chain Amyloidosis,” Radiology 288, no. 1 (2018): 73–80.
- 41J. Lu, Z. Yang, D. Tang, et al., “The Correlation of Left Atrial Dysfunction and Amyloid Load in Patients With Immunoglobulin Light-Chain Cardiac Amyloidosis: A 3T Cardiac Magnetic Resonance Study,” British Journal of Radiology 96 (2023): 20220985.
- 42J. Stojanovska, N. Topaloglu, K. Fujikura, et al., “Decreased Left Atrial Reservoir Strain Is Associated With Adverse Outcomes in Restrictive Cardiomyopathy,” Journal of Clinical Medicine Research 11, no. 14 (2022): 4116.
- 43L. Alwan, D. C. Benz, S. A. M. Cuddy, et al., “Current and Evolving Multimodality Cardiac Imaging in Managing Transthyretin Amyloid Cardiomyopathy,” JACC Cardiovascular Imaging 17, no. 2 (2024): 195–211.
- 44F. L. Ruberg and E. J. Miller, “Nuclear Tracers for Transthyretin Cardiac Amyloidosis: Time to Bone Up?: Time to Bone Up?” Circulation: Cardiovascular Imaging 6, no. 2 (2013): 162–164.
- 45A. Aftab, S. Szeto, Z. Aftab, and S. Bokhari, “Cardiac Sarcoidosis: Diagnosis and Management,” Frontiers in Cardiovascular Medicine 11 (2024): 1394075.
- 46A. R. Patel and C. M. Kramer, “Role of Cardiac Magnetic Resonance in the Diagnosis and Prognosis of Nonischemic Cardiomyopathy,” JACC Cardiovascular Imaging 10, no. 10 (2017): 1180–1193.
- 47A. L. Wand, J. Chrispin, E. Saad, M. Mukherjee, A. G. Hays, and N. A. Gilotra, “Current State and Future Directions of Multimodality Imaging in Cardiac Sarcoidosis,” Frontiers in Cardiovascular Medicine 8 (2021): 785279.
- 48R. Kandolin, J. Lehtonen, J. Airaksinen, et al., “Cardiac Sarcoidosis: Epidemiology, Characteristics, and Outcome Over 25 Years in a Nationwide Study,” Circulation 131, no. 7 (2015): 624–632.
- 49D. R. Okada, P. E. Bravo, T. Vita, et al., “Isolated Cardiac Sarcoidosis: A Focused Review of an Under-Recognized Entity,” Journal of Nuclear Cardiology 25, no. 4 (2018): 1136–1146.
- 50R. Ohanlon and D. J. Pennell, “Cardiovascular Magnetic Resonance in the Evaluation of Hypertrophic and Infiltrative Cardiomyopathies,” Heart Failure Clinics 5 (2009): 369–387.
- 51M. G. Trivieri, P. Spagnolo, D. Birnie, et al., “Challenges in Cardiac and Pulmonary Sarcoidosis: JACC State-of-the-Art Review,” Journal of the American College of Cardiology 76, no. 16 (2020): 1878–1901.
- 52D. H. Birnie, W. H. Sauer, F. Bogun, et al., “HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated With Cardiac Sarcoidosis,” Heart Rhythm 11, no. 7 (2014): 1305–1323.
- 53F. Terasaki, A. Azuma, T. Anzai, et al., “JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis – Digest Version,” Circulation Journal 83, no. 11 (2019): 2329–2388.
- 54C. D. Stefano, G. Bruno, M. A. Calle, et al., “Diagnostic and Predictive Value of Speckle Tracking Echocardiography in Cardiac Sarcoidosis,” Research Square (2019), doi:10.21203/rs.2.14614/v1.
10.21203/rs.2.14614/v1 Google Scholar
- 55D. J. Burstow, A. J. Tajik, K. R. Bailey, R. A. DeRemee, and C. P. Taliercio, “Two-Dimensional Echocardiographic Findings in Systemic Sarcoidosis,” American Journal of Cardiology 63, no. 7 (1989): 478–482.
- 56M. Aitken, M. Davidson, M. V. Chan, et al., “Prognostic Value of Cardiac MRI and FDG PET in Cardiac Sarcoidosis: A Systematic Review and Meta-Analysis,” Radiology 307, no. 2 (2023): e222483.
- 57J. P. Smedema, G. Snoep, M. P. G. van Kroonenburgh, et al., “Evaluation of the Accuracy of Gadolinium-Enhanced Cardiovascular Magnetic Resonance in the Diagnosis of Cardiac Sarcoidosis,” Journal of the American College of Cardiology 45, no. 10 (2005): 1683–1690.
- 58J. Jeudy, A. P. Burke, C. S. White, G. B. G. Kramer, and A. A. Frazier, “Cardiac Sarcoidosis: The Challenge of Radiologic-Pathologic Correlation: From the Radiologic Pathology Archives,” Radiographics 35, no. 3 (2015): 657–679.
- 59C. Tana, C. Mantini, I. Donatiello, et al., “Clinical Features and Diagnosis of Cardiac Sarcoidosis,” Journal of Clinical Medicine 10, no. 9 (2021): 1941.
- 60D. Marchetti, F. Buzzi, R. Di Febo, et al., “Role of Cardiac Magnetic Resonance in Inflammatory and Infiltrative Cardiomyopathies: A Narrative Review,” Journal of Clinical Medicine 13, no. 16 (2024): 4733.
- 61M. Sano, H. Satoh, K. Suwa, et al., “Intra-Cardiac Distribution of Late Gadolinium Enhancement in Cardiac Sarcoidosis and Dilated Cardiomyopathy,” World Journal of Cardiology 8, no. 9 (2016): 496–503.
- 62S. Greulich, D. Kitterer, J. Latus, et al., “Comprehensive Cardiovascular Magnetic Resonance Assessment in Patients With Sarcoidosis and Preserved Left Ventricular Ejection Fraction,” Circulation: Cardiovascular Imaging 9, no. 11 (2016): e005022.
- 63M. R. Patel, P. J. Cawley, J. F. Heitner, et al., “Detection of Myocardial Damage in Patients With Sarcoidosis,” Circulation 120, no. 20 (2009): 1969–1977.
- 64S. Greulich, C. C. Deluigi, S. Gloekler, et al., “CMR Imaging Predicts Death and Other Adverse Events in Suspected Cardiac Sarcoidosis,” JACC Cardiovascular Imaging 6, no. 4 (2013): 501–511.
- 65J. Wang, J. Zhang, N. Hosadurg, et al., “Prognostic Value of RV Abnormalities on CMR in Patients With Known or Suspected Cardiac Sarcoidosis,” JACC Cardiovascular Imaging 16, no. 3 (2023): 361–372.
- 66T. Ise, T. Hasegawa, Y. Morita, et al., “Extensive Late Gadolinium Enhancement on Cardiovascular Magnetic Resonance Predicts Adverse Outcomes and Lack of Improvement in LV Function After Steroid Therapy in Cardiac Sarcoidosis,” Heart 100, no. 15 (2014): 1165–1172.
- 67V. O. Puntmann, A. Isted, R. Hinojar, L. Foote, G. Carr-White, and E. Nagel, “T1 and T2 Mapping in Recognition of Early Cardiac Involvement in Systemic Sarcoidosis,” Radiology 285, no. 1 (2017): 63–72.
- 68P. Richardson, W. McKenna, M. Bristow, et al., “Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies,” Circulation 93, no. 5 (1996): 841–842.
- 69T. A. Manolio, K. L. Baughman, R. Rodeheffer, et al., “Prevalence and Etiology of Idiopathic Dilated Cardiomyopathy (Summary of a National Heart, Lung, and Blood) Institute Workshop,” American Journal of Cardiology 69, no. 17 (1992): 1458–1466.
- 70D. D. Sugrue, R. J. Rodeheffer, M. B. Codd, D. J. Ballard, V. Fuster, and B. J. Gersh, “The Clinical Course of Idiopathic Dilated Cardiomyopathy: A Population-Based Study,” Annals of Internal Medicine 117 (1992): 117–123.
- 71Y. Matsumura, J. Takata, H. Kitaoka, et al., “Long-Term Prognosis of Dilated Cardiomyopathy Revisited: An Improvement in Survival Over the Past 20 Years,” Circulation Journal 70, no. 4 (2006): 376–383.
- 72H. P. Schultheiss, D. Fairweather, A. L. P. Caforio, et al., “Dilated Cardiomyopathy,” Nature Reviews Disease Primers 5, no. 1 (2019): 32.
- 73B. Bozkurt, M. Colvin, J. Cook, et al., “Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association,” Circulation 134, no. 23 (2016): e579–e646.
- 74B. P. Halliday, A. J. Baksi, A. Gulati, et al., “Outcome in Dilated Cardiomyopathy Related to the Extent, Location, and Pattern of Late Gadolinium Enhancement,” JACC Cardiovascular Imaging 12, no. 8 pt. 2 (2019): 1645–1655.
- 75G. De Angelis, A. De Luca, M. Merlo, et al., “Prevalence and Prognostic Significance of Ischemic Late Gadolinium Enhancement Pattern in Non-Ischemic Dilated Cardiomyopathy,” American Heart Journal 246 (2022): 117–124.
- 76A. C. Alba, J. Gaztañaga, F. Foroutan, et al., “Prognostic Value of Late Gadolinium Enhancement for the Prediction of Cardiovascular Outcomes in Dilated Cardiomyopathy: An International, Multi-Institutional Study of the MINICOR Group,” Circulation: Cardiovascular Imaging 13, no. 4 (2020): e010105.
- 77S. Li, D. Zhou, A. Sirajuddin, et al., “T1 Mapping and Extracellular Volume Fraction in Dilated Cardiomyopathy: A Prognosis Study,” JACC Cardiovascular Imaging 15, no. 4 (2022): 578–590.
- 78F. Sanchez Tijmes, P. Thavendiranathan, J. A. Udell, M. A. Seidman, and K. Hanneman, “Cardiac MRI Assessment of Nonischemic Myocardial Inflammation: State of the Art Review and Update on Myocarditis Associated With COVID-19 Vaccination,” Radiology: Cardiothoracic Imaging 3, no. 6 (2021): e210252.
- 79P. Chareonthaitawee and M. Gutberlet, “Clinical Utilization of Multimodality Imaging for Myocarditis and Cardiac Sarcoidosis,” Circulation: Cardiovascular Imaging 16, no. 1 (2023): e014091.
- 80C. Urzua Fresno, F. Sanchez Tijmes, K. E. Shaw, et al., “Cardiac Imaging in Myocarditis: Current Evidence and Future Directions,” Canadian Association of Radiologists Journal 74, no. 1 (2023): 147–159.
- 81I. Joudar, N. Aichouni, S. Nasri, I. Kamaoui, and I. Skiker, “Diagnostic Criteria for Myocarditis on Cardiac Magnetic Resonance Imaging: An Educational Review,” Annals of Medicine and Surgery (London) 85, no. 8 (2023): 3960–3964.
- 82M. Al-Akchar, P. Shams, and J. Kiel, “ Acute Myocarditis,” in StatPearls (StatPearls Publishing, 2024).
- 83A. L. P. Caforio, G. Malipiero, R. Marcolongo, and I. S. Myocarditis, “A Clinical Overview,” Current Cardiology Reports 19, no. 7 (2017): 63.
- 84M. Gulati, P. D. Levy, D. Mukherjee, et al., “2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines,” Circulation 144, no. 22 (2021): e368–e454.
- 85A. J. M. Lewis, M. K. Burrage, and V. M. Ferreira, “Cardiovascular Magnetic Resonance Imaging for Inflammatory Heart Diseases,” Cardiovascular Diagnosis and Therapy 10, no. 3 (2020): 598–609.
- 86A. de Roos, “Diagnosis of Myocarditis at Cardiac MRI: The Continuing Quest for Improved Tissue Characterization,” Radiology 292, no. 3 (2019): 618–619.
- 87J. A. Luetkens, R. Homsi, D. Dabir, et al., “Comprehensive Cardiac Magnetic Resonance for Short-Term Follow-Up in Acute Myocarditis,” Journal of the American Heart Association 5, no. 7 (2016): e003603.
- 88V. M. Ferreira, J. Schulz-Menger, G. Holmvang, et al., “Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations,” Journal of the American College of Cardiology 72, no. 24 (2018): 3158–3176.
- 89P. Wheen, R. Armstrong, and C. A. Daly, “Recent Advances in T1 and T2 Mapping in the Assessment of Fulminant Myocarditis by Cardiac Magnetic Resonance,” Current Cardiology Reports 22, no. 7 (2020): 47.
- 90G. Georgiopoulos, S. Figliozzi, F. Sanguineti, et al., “Prognostic Impact of Late Gadolinium Enhancement by Cardiovascular Magnetic Resonance in Myocarditis,” Circulation: Cardiovascular Imaging 14, no. 1 (2021): e011492, https://doi.org/10.1161/circimaging.120.011492.
- 91W. J. McKenna and D. P. Judge, “Epidemiology of the Inherited Cardiomyopathies,” Nature Reviews Cardiology 18, no. 1 (2021): 22–36.
- 92R. Soler, C. Méndez, E. Rodríguez, R. Barriales, J. P. Ochoa, and L. Monserrat, “Phenotypes of Hypertrophic Cardiomyopathy. An Illustrative Review of MRI Findings,” Insights Imaging 9, no. 6 (2018): 1007–1020.
- 93B. J. Maron, M. Y. Desai, R. A. Nishimura, et al., “Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review,” Journal of the American College of Cardiology 79, no. 4 (2022): 372–389.
- 94M. Kawana, J. A. Spudich, and K. M. Ruppel, “Hypertrophic Cardiomyopathy: Mutations to Mechanisms to Therapies,” Frontiers in Physiology 13 (2022): 975076.
- 95J. G. Seidman and C. Seidman, “The Genetic Basis for Cardiomyopathy,” Cell 104, no. 4 (2001): 557–567.
- 96M. V. Sherrid, “On the Cause of Systolic Anterior Motion in Obstructive Hypertrophic Cardiomyopathy,” Journal of the American Society of Echocardiography 37, no. 8 (2024): 782–786.
- 97R. O'Hanlon, A. Grasso, M. Roughton, et al., “Prognostic Significance of Myocardial Fibrosis in Hypertrophic Cardiomyopathy,” Journal of the American College of Cardiology 56, no. 11 (2010): 867–874.
- 98S. R. Ommen, C. Y. Ho, I. M. Asif, et al., “2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines,” Circulation 149, no. 23 (2024): e1239–e1311.
- 99M. V. Sherrid, S. Bernard, N. Tripathi, et al., “Apical Aneurysms and Mid-Left Ventricular Obstruction in Hypertrophic Cardiomyopathy,” JACC Cardiovascular Imaging 16, no. 5 (2023): 591–605.
- 100A. Kiaos, G. N. Daskalopoulos, V. Kamperidis, A. Ziakas, G. Efthimiadis, and T. D. Karamitsos, “Quantitative Late Gadolinium Enhancement Cardiac Magnetic Resonance and Sudden Death in Hypertrophic Cardiomyopathy: A Meta-Analysis,” JACC Cardiovascular Imaging 17, no. 5 (2024): 489–497.
- 101A. D. Krahn, A. A. M. Wilde, H. Calkins, et al., “Arrhythmogenic Right Ventricular Cardiomyopathy,” JACC: Clinical Electrophysiology 8, no. 4 (2022): 533–553.
- 102D. Corrado, M. S. Link, and H. Calkins, “Arrhythmogenic Right Ventricular Cardiomyopathy,” New England Journal of Medicine 376, no. 1 (2017): 61–72.
- 103C. Basso, D. Corrado, B. Bauce, and G. Thiene, “Arrhythmogenic Right Ventricular Cardiomyopathy,” Circulation: Arrhythmia and Electrophysiology 5, no. 6 (2012): 1233–1246.
- 104G. D. Aquaro, A. De Luca, C. Cappelletto, et al., “Prognostic Value of Magnetic Resonance Phenotype in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy,” Journal of the American College of Cardiology 75, no. 22 (2020): 2753–2765.
- 105B. Pinamonti, A. M. Dragos, S. A. Pyxaras, et al., “Prognostic Predictors in Arrhythmogenic Right Ventricular Cardiomyopathy: Results From a 10-Year Registry,” European Heart Journal 32, no. 9 (2011): 1105–1113.
- 106N. Malik, M. Mukherjee, K. C. Wu, et al., “Multimodality Imaging in Arrhythmogenic Right Ventricular Cardiomyopathy,” Circulation: Cardiovascular Imaging 15, no. 2 (2022): e013725.
- 107D. Corrado, A. Zorzi, A. Cipriani, et al., “Evolving Diagnostic Criteria for Arrhythmogenic Cardiomyopathy,” Journal of the American Heart Association 10, no. 18 (2021): e021987.
- 108L. P. Bosman and A. Te Riele, “Arrhythmogenic Right Ventricular Cardiomyopathy: A Focused Update on Diagnosis and Risk Stratification,” Heart 108, no. 2 (2022): 90–97.
- 109F. I. Marcus, W. J. McKenna, D. Sherrill, et al., “Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Proposed Modification of the Task Force Criteria,” Circulation 121, no. 13 (2010): 1533–1541.
- 110N. Kawel, M. Nacif, A. E. Arai, et al., “Trabeculated (Noncompacted) and Compact Myocardium in Adults: The Multi-Ethnic Study of Atherosclerosis,” Circulation: Cardiovascular Imaging 5, no. 3 (2012): 357–366.
- 111J. A. Towbin and J. L. Jefferies, “Cardiomyopathies Due to Left Ventricular Noncompaction, Mitochondrial and Storage Diseases, and Inborn Errors of Metabolism,” Circulation Research 121, no. 7 (2017): 838–854.
- 112S. E. Petersen, B. Jensen, N. Aung, et al., “Excessive Trabeculation of the Left Ventricle: JACC: Cardiovascular Imaging Expert Panel Paper,” JACC Cardiovascular Imaging 16, no. 3 (2023): 408–425.
- 113S. E. Petersen, J. B. Selvanayagam, F. Wiesmann, et al., “Left Ventricular Non-Compaction,” Journal of the American College of Cardiology 46, no. 1 (2005): 101–105.
